Case Study: Application of LeukoLike Technology to Camouflage Nanoparticles from the Immune Recognition: Application of leukoLike technology to camouflage nanoparticles from the immune recognition

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Unknown venue

• Publication date

  2016-04-01

• Fields of study

  Materials Science, Chemistry, Engineering, Environmental Science

• Identifiers
  DOI 10.1142/9677
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• How endothelial cells regulate transmigration of leukocytes in the inflammatory response.

  2014cited by this paper
• Degradation and biocompatibility of multistage nanovectors in physiological systems.

  2014cited by this paper
• The effect of multistage nanovector targeting of VEGFR2 positive tumor endothelia on cell adhesion and local payload accumulation.

  2014cited by this paper
• Proteomic Profiling of a Biomimetic Drug Delivery Platform.

  2014cited by this paper
• Platelet-like Nanoparticles: Mimicking Shape, Flexibility, and Surface Biology of Platelets To Target Vascular Injuries

  2014cited by this paper
• Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors.

  2013cited by this paper
• Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface.

  2013cited by this paper
• Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions.

  2013cited by this paper
• Engineering multi-stage nanovectors for controlled degradation and tunable release kinetics.

  2013cited by this paper
• Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells.

  2013cited by this paper
• Exosome mimetics: a novel class of drug delivery systems

  2012cited by this paper
• Doxil®--the first FDA-approved nano-drug: lessons learned.

  2012cited by this paper
• Analysis on the current status of targeted drug delivery to tumors.

  2012cited by this paper
• Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?

  2012cited by this paper
• The nanomedicine revolution: part 2: current and future clinical applications.

  2012cited by this paper
• Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform

  2011cited by this paper
• Nanoparticle PEGylation for imaging and therapy.

  2011cited by this paper
• Bio-inspired, bioengineered and biomimetic drug delivery carriers

  2011cited by this paper
• Nanosystem drug targeting: Facing up to complex realities.

  2010cited by this paper
• Targeting of drugs and nanoparticles to tumors

  2010cited by this paper
• Molecular basis of leukocyte-endothelium interactions during the inflammatory response.

  2009cited by this paper
• Intravascular Delivery of Particulate Systems: Does Geometry Really Matter?

  2008cited by this paper
• Active targeting schemes for nanoparticle systems in cancer therapeutics.

  2008cited by this paper
• Vascular involvement in rheumatic diseases: 'vascular rheumatology'

  2008cited by this paper
• Nanoparticles in Medicine: Therapeutic Applications and Developments

  2008cited by this paper
• Seven challenges for nanomedicine.

  2008cited by this paper
• Antibiological barrier nanovector technology for cancer applications

  2007cited by this paper
• Shape effects of filaments versus spherical particles in flow and drug delivery.

  2007cited by this paper
• Infrared spectroscopy of proteins.

  2007cited by this paper
• Decreased circulation time offsets increased efficacy of PEGylated nanocarriers targeting folate receptors of glioma

  2007cited by this paper
• Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis.

  2006cited by this paper
• ICAM-2 mediates neutrophil transmigration in vivo: evidence for stimulus specificity and a role in PECAM-1-independent transmigration.

  2006cited by this paper
• Lymphocyte transcellular migration occurs through recruitment of endothelial ICAM-1 to caveola- and F-actin-rich domains

  2006cited by this paper
• Regulation of effector T cells by antigen-presenting cells via interaction of the C-type lectin MGL with CD45

  2006cited by this paper
• Advanced drug delivery systems that target the vascular endothelium.

  2006cited by this paper
• Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes.

  2005cited by this paper
• Nanotechnology: Opportunities and Challenges

  2003cited by this paper
• Viral mimicry of cytokines, chemokines and their receptors

  2003cited by this paper
• Control of immune responses by savenger liver endothelial cells.

  2003cited by this paper
• Decoding the Patterns of Self and Nonself by the Innate Immune System

  2002cited by this paper
• Analysis of the Roles of ICAM-1 in Neutrophil Transmigration Using a Reconstituted Mammalian Cell Expression Model: Implication of ICAM-1 Cytoplasmic Domain and Rho-Dependent Signaling Pathway1

  2001cited by this paper
• Adhesion Molecules: The Path to a New Understanding of Acute Inflammation.

  2000cited by this paper
• Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen.

  1998cited by this paper
• Early Phase Tumor Accumulation of Macromolecules: A Great Difference in Clearance Rate between Tumor and Normal Tissues

  1998cited by this paper
• Adhesion molecules and inflammatory injury

  1994cited by this paper
• Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1.

  1993cited by this paper
• The intrinsic migratory capacity of memory T cells contributes to their accumulation in rheumatoid synovium.

  1992cited by this paper
• Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy.

  1990cited by this paper
• Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis.

  1989cited by this paper
• A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

  1986cited by this paper
• Tumor angiogenesis: therapeutic implications.

  1971cited by this paper

• No citing papers are available for this paper.